Cancer care is at an inflection point. The traditional boundaries between academic and community oncology are dissolving, requiring a reimagined approach to patient care and clinical research. At City of Hope, we are implementing a national model that integrates breakthrough research with accessible, advanced treatment across diverse geographic regions.
Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form. Instead, they suggest that additional risk factors that promote tumor growth, like chronic inflammation, are a key trigger for tumor formation.
The thymus gland, in many ways, remains a mystery. The thymic regeneration division of the laboratory of Marcel van den Brink, president of City of Hope Los Angeles and City of Hope National Medical Center, is trying to tease out its secrets.
As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency.
The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.